Abstract:While it is now accepted that the gut microbiota contribute to the genotype-environment-lifestyle interactions triggering inflammatory bowel disease (IBD) episodes, efforts to identify the pathogen(s) that cause these diseases have met with limited success. The advent of culture-independent techniques for characterizing the structure and/or function of microbial communities (hereafter referred to as metagenomics) has provided new insights into the events associated with the onset, remission and recurrence of IBD. A large number of observational and/or case-control studies of IBD patients have confirmed substantive changes in gut bacterial profiles (dysbiosis) associated with disease. These types of studies have been augmented by new profiling approaches that support the identification of more ‘colitogenic' bacteria from numerically predominant taxa. Evidence of alterations in lesser abundant taxa such as the methanogenic archaea, to favor types that are more immunogenic, has also been forthcoming. Several recent longitudinal studies of patients with Crohn's disease have produced additional insights, including evidence for the role of ‘anti-inflammatory' microbiota in providing a protective effect and/or promoting remission. In summation, the implications of dysbiosis and restoration of a ‘healthy microbiota' in IBD patients requires definition beyond a taxonomic assessment of the changes in the gut microbiota during disease course. The available evidence does suggest that specific members of the gut microbiota can contribute either pro- or anti-inflammatory effects, and their ecological fitness in the large bowel affects the onset and recurrence of IBD. While metagenomics and related approaches offer the potential to provide novel and important insights into these microbiota and thereby the pathophysiology of IBD, we also need to better understand factors affecting the ecological fitness of these microbes, if new treatment of IBD patients are to be delivered.

New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease

The oral-gut microbiome axis in inflammatory bowel disease: from inside to insight

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease

The involvement of oral bacteria in inflammatory bowel disease

Intestinal microecology dysbiosis in inflammatory bowel disease: Pathogenesis and therapeutic strategies

Effect of Dysbiosis of Intestinal Microbiota in Inflammatory Bowel Disease

Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases

[Oral microbiota and inflammatory bowel disease]

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease.

New Insights into Bacterial Mechanisms and Potential Intestinal Epithelial Cell Therapeutic Targets of Inflammatory Bowel Disease

Linking Periodontitis with Inflammatory Bowel Disease through the Oral–Gut Axis: The Potential Role of Porphyromonas gingivalis

Unraveling the Link between Periodontitis and Inflammatory Bowel Disease: Challenges and Outlook

Inflammatory Bowel Disease: A Potential Result from the Collusion Between Gut Microbiota and Mucosal Immune System

The emerging role of the gut microbiota and its application in inflammatory bowel disease

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease

Recent Progress on the Role of Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease.

New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Unraveling the Oral-Gut axis: Interconnection between Periodontitis and IBD, Current Challenges, and Future Perspective